# Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units

> **NCT02213796** · PHASE4 · COMPLETED · sponsor: **Sutep Jaruratanasirikul** · enrollment: 9 (actual)

## Conditions studied

- Initial Phase of Severe Sepsis and Septic Shock

## Interventions

- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT02213796
- **Lead sponsor:** Sutep Jaruratanasirikul
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213796, "Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02213796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*